VERU INC. (The Female Health Company) - 10-K Summary
Business Context and Reporting Period
Company: The Female Health Company (VERU Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2008
Business Overview: The Company manufactures, markets, and sells the FC female condom, the only FDA-approved product under a woman's control providing dual protection against unintended pregnancy and sexually transmitted diseases (STDs), including HIV/AIDS. The Company also markets FC2, a second-generation nitrile polymer product that is more cost-effective to produce. Products are sold in 116 countries, primarily through public sector agencies (e.g., UNFPA, USAID) and commercial partners.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Net Revenues | $25,634,126 | $19,319,889 |
| Gross Profit | $10,729,801 | $7,156,315 |
| Gross Margin | 41.9% | 37.0% |
| Operating Income | $3,183,725 | $903,397 |
| Net Income | $4,966,768 | $1,693,913 |
| Net Income Attributable to Common Stockholders | $4,829,262 | $1,532,665 |
| Diluted EPS | $0.18 | $0.06 |
| Cash Flow from Operations | $4,244,398 | ($80,988) |
| Working Capital | $9,249,040 | $7,171,798 |
| Total Assets | $13,830,738 | $11,193,548 |
| Stockholders' Equity | $9,709,202 | $7,447,459 |
Debt and Liquidity: The Company has a revolving credit facility with Heartland Bank allowing borrowings up to $1.5 million. No amounts were outstanding under this facility as of September 30, 2008. Cash and restricted cash totaled approximately $2.13 million at period end.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 33% ($6.3 million) driven by higher demand for female condoms and the introduction of royalty income ($105,876) from licensing intellectual property to Hindustan Latex Limited in India.
- Profitability: Net income attributable to common stockholders increased 215% ($3.3 million). This was driven by a 50% increase in gross profit due to improved margins on FC and a higher mix of the more profitable FC2 product.
- Non-Operating Items: The Company recorded a significant foreign currency transaction gain of $966,736 in 2008, compared to a loss of $70,488 in 2007. This gain was primarily due to the translation of intercompany trade accounts.
- Operating Expenses: Total operating expenses increased 21% ($1.3 million), primarily due to increased selling, general, and administrative expenses (20% increase) related to full-year salaries for new positions, Sarbanes-Oxley compliance costs, and performance bonuses.
- Capital Structure: The Company redeemed all 56,000 shares of Class A Series 1 Convertible Preferred Stock and repurchased 165,773 shares of Class A Series 3 Convertible Preferred Stock during the year.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- FC2 Approval: The FDA's OB/GYN Device Advisory Committee unanimously voted in December 2008 that the FC2 female condom is approvable with a single condition regarding labeling. Final FDA approval is pending confirmation of package labeling.
- Backlog: As of December 10, 2008, the product order backlog was approximately $10.8 million, a significant increase from $6.6 million the prior year.
- Strategy: The Company aims to accelerate market penetration through the lower-cost FC2 product and expand distribution in the public sector, particularly in India and Africa.
Risks and Contingencies:
- Single Product Reliance: The Company derives virtually all revenue from the female condom. Future results depend entirely on demand for this single product.
- Regulatory Risk: Operations are subject to FDA and international regulatory approvals. Failure to maintain approval for FC or secure approval for FC2 could materially adversely affect the business.
- Customer Concentration: Significant customers include UNFPA (19% of sales), John Snow, Inc. (25% of sales), and Sekunjalo (17% of sales). Loss of these contracts would be material.
- Foreign Currency: Manufacturing costs are denominated in British pounds and Malaysian ringgit, while sales are in USD and GBP. Fluctuations in exchange rates impact gross margins.
Investor Verification Checklist
- FC2 FDA Approval Status: Verify the final FDA approval status of the FC2 product, as this is critical for cost reduction and volume growth.
- Customer Contract Renewals: Confirm the renewal status of major contracts with UNFPA, USAID (via John Snow, Inc.), and Sekunjalo, which collectively represent over 60% of sales.
- Foreign Currency Exposure: Monitor the GBP/USD exchange rate, as a weaker dollar increases manufacturing costs and reduces gross margins.
- Backlog Conversion: Track the conversion of the $10.8 million backlog into recognized revenue in fiscal 2009.
- Preferred Stock Obligations: Review remaining obligations related to the Class A Series 3 Convertible Preferred Stock (307,602 shares outstanding) and associated dividend payments.